[go: up one dir, main page]

UY29857A1 - Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica. - Google Patents

Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.

Info

Publication number
UY29857A1
UY29857A1 UY29857A UY29857A UY29857A1 UY 29857 A1 UY29857 A1 UY 29857A1 UY 29857 A UY29857 A UY 29857A UY 29857 A UY29857 A UY 29857A UY 29857 A1 UY29857 A1 UY 29857A1
Authority
UY
Uruguay
Prior art keywords
therapeutics
derivatives
amino
preparation
application
Prior art date
Application number
UY29857A
Other languages
English (en)
Inventor
Thomas Anne
Despeyroux Pierre
Gilles Courtemanche
Geslin Michel
Augereau Jean Michel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29857(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY29857A1 publication Critical patent/UY29857A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a derivados de la 4-amino-quinazolina, de fórmula general (I), en forma de base o de sal de adición a un ácido, así como en forma de hidrato o de solvato. Procedimiento de preparación y aplicación en terapéutica.
UY29857A 2005-10-12 2006-10-12 Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica. UY29857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510409A FR2891829A1 (fr) 2005-10-12 2005-10-12 Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
UY29857A1 true UY29857A1 (es) 2007-05-31

Family

ID=36645639

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29857A UY29857A1 (es) 2005-10-12 2006-10-12 Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.

Country Status (5)

Country Link
AR (1) AR056688A1 (es)
FR (1) FR2891829A1 (es)
TW (1) TW200732308A (es)
UY (1) UY29857A1 (es)
WO (1) WO2007042669A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
AU2009249246A1 (en) 2008-05-22 2009-11-26 Allergan, Inc. Bicyclic compounds having activity at the CXCR4 receptor
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
MX387806B (es) 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US20250066358A1 (en) * 2021-12-09 2025-02-27 Bala Therapeutics, Inc. Inhibitors of Menin-MLL Interaction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126087A1 (en) * 1982-09-24 1984-11-28 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
CA2460594A1 (en) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Mch receptor antagonists
CA2488635C (en) * 2002-06-12 2012-10-23 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
CA2508681A1 (en) * 2002-12-11 2004-06-24 7Tm Pharma A/S Quinoline compounds for use in mch receptor related disorders
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
EP1844023A1 (en) * 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity

Also Published As

Publication number Publication date
WO2007042669A2 (fr) 2007-04-19
WO2007042669A3 (fr) 2007-05-31
TW200732308A (en) 2007-09-01
AR056688A1 (es) 2007-10-17
FR2891829A1 (fr) 2007-04-13

Similar Documents

Publication Publication Date Title
NL301139I2 (nl) Selumetinibwaterstofsulfaat, desgewenst in watervrije vorm of in de vorm van een solvaat
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
UY30115A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en terapeutica
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
UY28855A1 (es) Derivados de la 1-amino-ftalazina su preparación y su uso en terapia
ECSP056111A (es) Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
EA201070786A1 (ru) Бензофуропиримидиноны
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
ATE504556T1 (de) Herstellung von natriumdiformiat
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
UY29690A1 (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica.
UY29518A1 (es) Derivados de alquil-, alquenil- y alquinilcarbamatos, su preparación y su aplicación en terapéutica.
MX2009000768A (es) Lactamas macrociclicas.
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
UY32496A (es) Derivados de n-[(6-aza-biciclo[3.2.1]oct-5-il)-aril-metil]-heterobenzamida, su preparación y su aplicación en terapéutica.
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
UY29040A1 (es) Procedimiento de amino-tropano, su preparación y aplicación en terapéutica
GB0602951D0 (en) Organic Compounds

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120515